Selecting a new mass tort to pursue is more of a business intelligence exercise than a legal one. While the underlying legal merits are essential, the financial success of a campaign hinges on a strategic evaluation of the opportunity. A solid framework helps balance the potential rewards with the inherent risks and costs.

Think of it as a three-legged stool: average case value, competition, and filing timeline. If one leg is weak, the entire venture can become unstable. A high-value case might be worthless if the market is too saturated with competing ads, driving acquisition costs through the roof. Conversely, a low-competition tort is no bargain if the potential settlements are too small to justify the marketing spend.

Using this framework transforms case selection from a gut feeling into a data-driven decision. It's about finding the sweet spot where a strong legal case meets a favorable market environment.

The most profitable mass torts are often identified before they become common knowledge. This means monitoring the sources that signal the birth of a new litigation. The primary place to watch is the docket of the Judicial Panel on Multidistrict Litigation (JPML). When multiple federal lawsuits concerning a single product or event begin to pile up, parties will file a motion with the JPML to consolidate the cases into a multidistrict litigation (MDL). Tracking these filings provides a direct view into the next wave of mass torts.

Beyond court filings, the triggers for new torts often come from science and regulatory agencies. A sudden FDA warning on a popular drug, a medical device recall, or a new peer-reviewed study can be the spark. For instance, the litigation connecting the herbicide Paraquat to Parkinson's disease gained significant momentum after several epidemiological studies were published suggesting a strong link. Attorneys who monitor these scientific and regulatory channels can position themselves months or even years ahead of the competition.

Identifying a promising tort is only half the battle. The other half is acquiring plaintiffs at a cost that makes financial sense. This requires a sharp focus on the Return on Marketing Investment (ROMI), which measures the profitability of your advertising efforts.

The key dynamic to manage is the relationship between timing and acquisition cost. When a tort is new, like the Depo-Provera litigation (MDL 3140) concerning pseudotumor cerebri, awareness is low. This means fewer firms are competing for keywords and ad space, keeping lead costs down. However, it also means more effort is required to educate potential claimants.

Contrast this with a mature litigation like Camp Lejeune. The PACT Act created a massive, well-defined claimant pool, and the story received extensive media coverage. This led to extreme market saturation. Hundreds of firms jumped in, driving advertising costs to astronomical levels. While the case values are high, the cost to sign a single client can erode profit margins significantly for firms that entered the race late.

Assessing market saturation involves looking at search engine keyword costs, the volume of television and social media advertising, and the number of firms listed on referral services for that specific tort. If the landscape is already crowded, it might be more strategic to focus resources on the next Camp Lejeune instead of the current one.

Now, let's review some of the key ideas from this section.

Time to check what you've learned.

Mastering this blend of legal monitoring, scientific awareness, and economic analysis is what separates firms that simply participate in mass torts from those that build highly profitable practices around them.